UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000017650
Receipt No. R000020452
Scientific Title Clinical usefulness of fecal calprotectin for ulcerative colitis
Date of disclosure of the study information 2015/05/22
Last modified on 2019/09/08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Clinical usefulness of fecal calprotectin for ulcerative colitis
Acronym Triple-C study
Scientific Title Clinical usefulness of fecal calprotectin for ulcerative colitis
Scientific Title:Acronym Triple-C study
Region
Japan

Condition
Condition ulcerative colitis
Classification by specialty
Gastroenterology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate relation between fecal calprotectin/fecal occult blood test and endoscopic severity
To evaluate usefulness of fecal calprotectin/fecal occult blood test on long-term prognosis of UC
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes To evaluate relation between fecal calprotectin/fecal occult blood test and endoscopic severity
To evaluate usefulness of fecal calprotectin/fecal occult blood test on long-term prognosis of UC
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1 Patients who were diagnosed as UC
2 Patients who were/will be conducted colonoscopy
3 Informed consent was obtained prior to clinical study
4 Patients whose age are equal to/more than 18 years -old.

In addition
clinical remission is obtained in case of entry for investigation of clinical outcome
Key exclusion criteria Patients who received total colectomy
Patients who received bowel resection within 6 months prior to entry of this study
Patients who have recent GI bleeding, infectious colitis or colonic adenocarcinoma.
Patients who received leukocyte or granulocyte- monocyte apheresis therapy.
Patients who received non-steroid anti-inflammatory agent (NSAID).
Target sample size 2000

Research contact person
Name of lead principal investigator
1st name Takanori
Middle name
Last name Kanai
Organization School of Medicine, Keio University
Division name Division of Gastroenterology and Hepatoligy
Zip code 1608582
Address 35 Shinanomachi, Shinjuku-KU Tokyo
TEL 81-3-3353-1211
Email takagast@z2.keio.jp

Public contact
Name of contact person
1st name Makoto
Middle name
Last name Naganuma
Organization School of Medicine, Keio University
Division name Division of Gastroenterology and Hepatoligy
Zip code 1608582
Address 35 Shinanomachi, Shinjuku-KU Tokyo
TEL 03-3353-1211
Homepage URL
Email nagamakoto@z7.keio.ac.jp

Sponsor
Institute School of Medicine, Keio University
Institute
Department

Funding Source
Organization thermoscientific company
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Keio Universisy, School of Medicine
Address 35 Shinanomachi. Shinjuku-ku, Tokyo
Tel 03-333-1211
Email med-rinri-jimu@adst.keio.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 05 Month 22 Day

Related information
URL releasing protocol https://www.ncbi.nlm.nih.gov/pubmed/31394288
Publication of results Partially published

Result
URL related to results and publications https://www.ncbi.nlm.nih.gov/pubmed/31394288
Number of participants that the trial has enrolled 879
Results
In a nationwide study of patients with UC in Japan, we found that the level of FCP and FIT could each identify patients with endoscopic markers of disease severity.The combination of FCP and FIT results can identify patients in remission who are at risk for disease recurrence.
Results date posted
2019 Year 09 Month 08 Day
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
To date, most studies on the usefulness of fecal biomarkers have been conducted with relatively small numbers of patients. There have been only a few large multicenter cohort studies on the efficacy of fecal biomarkers for clinical recurrence in patients with UC. Furthermore, it remains unclear whether FCP or FIT levels can reflect the extension of inflammation. Therefore, this nationwide prospective study aims to compare FCP and FIT on the usefulness of assessing endoscopic severity in UC and predicting short- and middle-term prognosis in patients in clinical remission.
Participant flow
A total of 879 patients with UC were enrolled in this study from March 2015 to March 2017. These patients had been recruited from 16 institutions and were randomly enrolled. This study consisted of two cohorts.
Adverse events
None
Outcome measures
The primary endpoint in Cohort 1 was to evaluate the correlation between FCP/FIT and endoscopic severity. The primary endpoint in Cohort 2 was to assess the association between FCP or FIT level at baseline and clinical recurrence 
for 12 months in patients with UC in clinical remission.
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2014 Year 10 Month 16 Day
Date of IRB
2014 Year 12 Month 12 Day
Anticipated trial start date
2015 Year 01 Month 01 Day
Last follow-up date
2018 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
2008 Year 12 Month 12 Day
Date analysis concluded
2018 Year 12 Month 15 Day

Other
Other related information Secondary points are as below
To evaluate fecal calprotectin and clinical severity/other biomarkers such as fecal occult blood test or CRP.

Management information
Registered date
2015 Year 05 Month 22 Day
Last modified on
2019 Year 09 Month 08 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020452

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.